Drug therapy for juvenile arthritis

Area of Science:

• Pediatric Rheumatology
• Immunology
• Pharmacology

Background:

• Juvenile arthritis (JA) encompasses diverse rheumatic conditions with varied symptoms.
• The heterogeneity of JA necessitates tailored therapeutic strategies.
• Most children with JA experience significant improvement with initial treatments, particularly those with pauciarticular disease.

Purpose of the Study:

• To outline a rational therapeutic approach for juvenile arthritis based on disease heterogeneity.
• To guide the selection of first- and second-line treatments for different JA subtypes.
• To emphasize the importance of timely intervention for patients with poor prognoses.

Main Methods:

• Review of current treatment guidelines and clinical evidence for juvenile arthritis.
• Classification of JA based on articular involvement (pauciarticular vs. polyarticular) and serological status (RF-positive/negative).
• Analysis of treatment outcomes and prognoses associated with different therapeutic strategies.

Main Results:

• Pauciarticular JA generally responds well to first-line treatments.
• Patients with polyarticular, RF-positive JA or early-onset systemic-onset disease require early second-line treatment for optimal joint function.
• Injectable gold, antimalarials, auranofin, and sulfasalazine are considered second-line options, with specific indications.
• Cytotoxic/antimetabolic and corticosteroid therapies are reserved for refractory cases or specific situations.

Conclusions:

• A rational, individualized approach to drug therapy is mandatory for juvenile arthritis.
• Early and appropriate selection of second-line treatments can significantly improve long-term joint outcomes for high-risk patients.
• Minimizing corticosteroid use and aiming for remission in the best possible condition are key therapeutic goals.